Abstract:Lung cancer is a lethal disease, and early diagnosis with the aid of biomarkers such as HSP90α protein can certainly assist the doctors to start treatment of patient at the earliest and can save their lives. To analyse the diagnostic value of HSP90α expression in lung cancer patients by collecting data of patients through IoT devices to avoid delay in treatments, a study has been presented in this paper where the significance of HSP90α biomarker is highlighted in early diagnosis of patients suffering from lung cancer. The second objective of the research study is to examine the correlation between the appearance level of HSP90α biomarker and the clinicopathological features of lung cancer. It is also evaluated whether the changes in HSP90α index are indicative or noteworthy before and after surgery of lung cancer patients. An observatory study of 78 patients with lung cancer in Qinhuangdao Hospital is presented in this paper where the samples were collected from June 2018 to March 2020. Their data were collected through IoT devices used in the latest healthcare facilities of the hospital. The ELISA method was utilized to identify the level of plasma HSP90 and to analyse HSP90 levels between the lung cancer group and healthy group of people. The relationship between HSP90 and the clinical pathological features of 78 patients suffering from lung cancer was analysed. An electrochemical luminescence method was used to detect CEA, NSE, SCC, and CYFRA21-1 levels. ROC curve and box plots were used to determine the analytic value of HSP90 and other biomarkers used in lung cancer diagnosis. Forty-two patients with moderate to early stage lung cancer with surgical correction were selected, and paired sample T test was used to analyse HSP90 levels before and after surgery. The plasma HSP90 level of lung cancer patients was quite higher as compared to the group of healthy people as per the values depicted in the research study. Second, HSP90 levels are substantially higher in pathologic type, differentiation degree, stage, and the existence of the lung, liver, and bone metastases (P < 0.05). The level of HSP90 expression was largely impacted by a few factors such as sex, age, smoking, and tumour location (P > 0.05). The ROC value for HSP90 was 0.599, while the area under the curve of HSP90 combined with other four tumour markers was 0.915 in the presented case study, indicating the presence of lung cancer. Patients with lung cancer had statistically significant differences in HSP90 expression levels before and after surgery (P < 0.05). It is concluded that the expression level of plasma HSP90α in lung cancer patients increases remarkably; therefore, HSP90 can be used to monitor presence of lung cancer before and after surgery in the patients.

Co-overexpression of Hsp90-β and annexin A1 with a significantly positive correlation contributes to the diagnosis of lung cancer.

Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients

Expression of Hsp90α in blood of patients with lung cancer

Diagnostic value of HSP90α and Related Markers in Lung Cancer

Identification and verification of Hsp90-beta as a potential serum biomarker for lung cancer (vol 4, pg 874, 2014)

Elevated Serum Annexin A1 As Potential Diagnostic Marker for Lung Cancer: a Retrospective Case-Control Study.

Clinical significance of heat shock protein 90 expression in patients with lung adenocarcinoma

Increased Level of Hsp90-Beta in Bronchoalveolar Lavage Fluid Correlates with Lymphatic Invasion and Advanced Stage of Lung Cancer Patients

Increased Level of Annexin A1 in Bronchoalveolar Lavage Fluid As a Potential Diagnostic Indicator for Lung Cancer

Impact of HSP90 α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients

Expression and Clinical Significance of Hsp90αin Non-smal l Lung Cancer Tissues

Elevation of Serum HSP90α Correlated with the Clinical Stage of Non-Small Cell Lung Cancer

Elevated of HSP90 associates with expression of EGFR levels and predicts poor prognosis in non-small cell lung cancer patients

Analysis of the prognostic, diagnostic and immunological role of HSP90α in malignant tumors

Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment Responses.

Serum HSP90α in the Clinical Stage of Non-Small Cell Lung Cancer

Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer

Elevated Hsp90-beta Contributes to Differential Diagnosis of Pleural Effusion Caused by Lung Cancer and Correlates with Malignant Biological Behavior of Lung Cancer

Prognostic Value of the Mrna Expression of Members of the HSP90 Family in Non-Small Cell Lung Cancer

Expression of heat shock protein 90α in hepatocellular carcinoma and its significance